R
R. P. Hertzberg
Publications - 3
Citations - 306
R. P. Hertzberg is an academic researcher. The author has contributed to research in topics: Topoisomerase & Camptothecin. The author has an hindex of 3, co-authored 3 publications receiving 305 citations.
Papers
More filters
Journal Article
Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
Wai Kwong Eng,F. L. Mccabe,K. B. Tan,M R Mattern,G. A. Hofmann,R. D. Woessner,R. P. Hertzberg,Randall K. Johnson +7 more
TL;DR: The results suggest that development of resistance to inhibitors of topoisomerase I can occur by down-regulation of the target enzyme, thus reducing the production of lethal enzyme-mediated DNA damage.
Journal ArticleDOI
Synthesis of Water-Soluble (Aminoalkyl)camptothecin Analogues: Inhibition of Topoisomerase I and Antitumor Activity.
William D. Kingsbury,Jeffrey C. Boehm,D. R. Jakas,K. G. Holden,S. M. Hech,G. Gallagher,M. J. Caranfa,Francis L. McCabe,Leo F. Faucette,Randall K. Johnson,R. P. Hertzberg +10 more
TL;DR: 9-[(dimethylamino)methyl]-10-hydroxycamptothecin (4, SK&F 104864) for development as an antitumor agent demonstrated broad-spectrum activity in preclinical tumor models and is currently undergoing Phase I clinical trials in cancer patients.
Journal Article
Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content.
R. D. Woessner,Wai-Kwong Eng,G. A. Hofmann,D. J. Rieman,Francis L. McCabe,R. P. Hertzberg,M R Mattern,K. B. Tan,Randall K. Johnson +8 more
TL;DR: P388 cells have the potential to become highly resistant to CPT by severely curtailing topoisomerase I expression; in these circumstances, topoisomersase I and II activities are regulated coordinately.